About VBI Vaccines
VBI Vaccines is a company based in Cambridge (United States) founded in 2001. It operates as a Direct-to-Consumer (D2C) and B2B2C. VBI Vaccines has raised $65.07 million across 23 funding rounds from investors including Blackstone, National Research Council Canada and RTW Investments. VBI Vaccines has completed 2 acquisitions, including Epixis and SciVac Therapeutics. VBI Vaccines offers products and services including PreHevbrio and VBI-2601. VBI Vaccines operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter Cambridge, United States
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vbi Vaccines Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$65.07 M (USD)
in 23 rounds
-
Latest Funding Round
Not available
-
Investors
Blackstone
& 7 more
-
Employee Count
Not available
-
Investments & Acquisitions
Epixis
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of VBI Vaccines
VBI Vaccines offers a comprehensive portfolio of products and services, including PreHevbrio and VBI-2601.
A hepatitis B vaccine is developed for prevention.
An HBV immunotherapeutic is designed for treatment purposes.
People of VBI Vaccines
Unlock access to complete
Unlock access to complete
Funding Insights of VBI Vaccines
VBI Vaccines has successfully raised a total of $65.07M across 23 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in VBI Vaccines
VBI Vaccines has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Blackstone, National Research Council Canada and RTW Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Life Sciences focused VC firm investing in the US
|
Locked | Locked | Locked |
Investor details for VBI Vaccines
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by VBI Vaccines
VBI Vaccines has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Epixis and SciVac Therapeutics.
Investment portfolio details for VBI Vaccines
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Hepatitis B vaccine development was focused on by SciVac Therapeutics.
|
Locked | Locked | 2005 | Locked | |
|
French biotech developing e-VLP (virus like particles) immunotherapies for Hep-C. Acquired by VBI Vaccines in 2011
|
Locked | Locked | 2003 | Locked |
Complete acquisition details for VBI Vaccines
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - VBI Vaccines
Detailed financials for VBI Vaccines
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vbi Vaccines Comparisons
Peer comparison for VBI Vaccines
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of VBI Vaccines
VBI Vaccines operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of VBI Vaccines
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vbi Vaccines
Complete news archive for VBI Vaccines
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VBI Vaccines
VBI Vaccines was founded in 2001 and raised its 1st funding round 6 years after it was founded.
VBI Vaccines is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
VBI Vaccines is a funded company, having raised a total of $65.07M across 23 funding rounds to date.
VBI Vaccines is focused on the development of vaccine and immunotherapeutic candidates aimed at addressing significant unmet needs in infectious diseases and oncology. The company operates in the healthcare sector, targeting conditions such as hepatitis B and various cancers with innovative solutions. Their pipeline includes both prophylactic vaccines to prevent diseases and therapeutic immunotherapeutics to treat existing conditions by harnessing the immune system. Operations are supported by facilities in the United States, Canada, and Israel, covering research, development, and manufacturing activities.
VBI Vaccines's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
VBI Vaccines offers PreHevbrio and VBI-2601.
VBI Vaccines has made 2 acquisitions, including Epixis, and SciVac Therapeutics.
VBI Vaccines has 8 investors. Key investors include Blackstone, National Research Council Canada, RTW Investments, Opko Health, and Arch Venture Partners.